Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Innovent’s nAMD Drug Succeeds in Phase 2 Trial
Innovent Biologics announced that its second Phase 2 clinical trial of efdamrofusp alfa (R&D code: IBI302), a high-dose recombinant human VEGFR-Fc-Human CR1 fusion protein injection, has achieved its primary endpoint in treating Chinese subjects with neovascular age-related macular degeneration (nAMD).…
2023 Recap: Top 20 Ophthalmic Collaborations of the Year
As we bid farewell to 2023, it’s time to reflect on the remarkable collaborations that have shaped the landscape of ophthalmic innovation. The past year witnessed groundbreaking partnerships between pharmaceutical giants, tech innovators, and research institutions, all aimed at advancing…
Top 12 Gene Therapies for Eye Diseases and Blindness
In a groundbreaking era of medical research, scientists and clinicians are spearheading novel gene therapies that hold promise for transforming the landscape of eye disease treatment. These cutting-edge interventions address a spectrum of conditions ranging from Usher Syndrome and retinoschisis…
2023 Recap: Top 15 Ophthalmic Medical Devices
In a groundbreaking year for ophthalmic advancements, 2023 has witnessed the launch of cutting-edge medical devices that promise to reshape the landscape of eye care. From augmented reality headsets to innovative surgical systems, the field is experiencing a wave of…
AI Detects Retinopathy of Prematurity with 100% Accuracy
In a study published in JAMA Ophthalmology, researchers from Oregon Health & Science University (OHSU) alongside international collaborators have unveiled an artificial intelligence (AI) technology capable of independently detecting all severe cases of a condition leading to blindness in prematurely…
MediPrint Finalizes Glaucoma Contact Lens Study
MediPrint Ophthalmics has successfully completed its SIGHT-2 phase 2b study, showcasing the efficacy of its innovative product, LL-BMT1, against a control group using bimatoprost 0.01% ophthalmic solution. LL-BMT1, a preservative-free, weekly drug-eluting contact lens, utilizes the company’s 3D printing technology,…
Sandoz Finalizes Acquisition of Cimerli from Coherus
Sandoz has successfully completed the acquisition of the United States biosimilar, Cimerli (ranibizumab-eqrn), from Coherus BioSciences. This strategic move underscores Sandoz’s commitment to expanding its portfolio in the biopharmaceutical sector, particularly in the area of biosimilars. The transaction, initially announced…
Amring Pharma Announces Name Change to Nordic Pharma
In a significant corporate rebranding, Amring Pharmaceuticals has officially adopted the name Nordic Pharma. This renaming marks a new chapter following the acquisition by Nordic Group, a subsidiary of Sever Life Sciences, on June 1, 2023. The strategic move aims…
Glaukos’ iDose TR Hits the Commercial Market
Glaukos Corporation’s iDose TR, using Celanese’s VitalDose EVA (Ethylene Vinyl Acetate), to provide sustained drug release for the treatment of glaucoma has officially entered the commercial market. Having received FDA approval in December, iDose TR represents a notable departure from…
Study Uncovers Eye’s Defense Against Brain Infections
In a study published in the journal Nature, researchers have found that vaccines injected into the eyes of mice can effectively combat the herpes virus, a leading cause of brain encephalitis. Contrary to expectations, the vaccine triggers an immune response…